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Abstract 
Background: Few studies have investigated the association between coronary artery calcium (CAC) progression and 
arterial stiffness measured by brachial‑ankle pulse wave velocity (baPWV). We examined the influence of the severity 
of baseline baPWV on CAC progression in a large prospective cohort.
Methods: A total of 1600 subjects who voluntarily participated in a comprehensive health‑screening program 
between March 2010 and December 2013 and had baseline baPWV as well as CAC on baseline and serial follow‑up 
computed tomography performed approximately 2.7 ± 0.5 years apart were enrolled in the study.
Results: A total of 1124 subjects were included in the analysis (1067 men; mean age, 43.6 ± 5.1 years). An increased 
CAC score was found in 318 subjects (28.3 %) during the follow‑up period. Baseline higher baPWV was significantly 
correlated with CAC progression, especially in subjects with third‑ and fourth‑quartile values (adjusted odds ratio [OR] 
2.04; 95 % confidence interval [CI] 1.33–3.15 and OR 2.14; 95 % CI 1.34–3.41, respectively) compared with the lowest‑
quartile values (P for trend <0.001). A similar effect was observed in diabetic subjects. Among the 835 subjects with 
a baseline CAC score = 0, progression to CAC score >0 was associated with male sex, diabetes, and higher baPWV. 
However, among the 289 individuals with a baseline CAC score >0, only the presence of CAC itself was predictive of 
CAC progression.
Conclusions: Higher arterial stiffness measured by baPWV could be significantly associated with CAC progression.
Keywords: Arterial stiffness, baPWV, Cardiometabolic risk factors, Cardiovascular disease (CVD), Coronary arterial 
calcification
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Background
The presence of coronary artery calcium (CAC) is sig-
nificantly correlated with the risk of coronary heart dis-
ease [1] and poor prognosis [2–6]. CAC can be measured 
using either electron beam computed tomography (CT) 
or multidetector CT (MDCT) by the Agatston scor-
ing method [7]. In both men and women, CT-measured 
CAC values are highly sensitive for the presence of ≥50 % 
angiographic stenosis but only moderately specific (91 
and 49 %, respectively) [8]. However, the absence of CAC 
is highly predictive of the absence of significant coronary 
artery stenosis and is used to identify individuals at low 
clinical risk [9].
Although serial measurements of CAC may be use-
ful to assess the activity of the atherosclerotic process or 
monitor the efficacy of medications used to slow or halt 
the progression of coronary atherosclerosis, serial CAC 
studies are of unproven clinical value and are thus not 
recommended. However, several studies have shown an 
association between CAC progression and traditional 
risk factors and increased risk of cardiovascular events 
[10–12].
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Arterial stiffness measured by aortic pulse wave 
velocity (PWV) is a potential predictor of cardiovascu-
lar events [13, 14]. Brachial-ankle pulse wave velocity 
(baPWV), a promising technique used to assess arte-
rial stiffness, is simple, noninvasive, and nonradiating. 
BaPWV may provide information similar to that derived 
from central PWV [15] and is independently associated 
with the presence and severity of coronary artery disease 
(CAD) [16–18].
Because few studies have investigated the association 
between baPWV and CAC progression, it is unclear 
whether baPWV can be used to identify subjects with 
progressive subclinical CAC. We examined the influence 




The Kangbuk Samsung Health Study (KSHS) is a Korean 
cohort study enrolling all men and women 18 years of age 
or older who voluntarily undergo comprehensive health-
screening examinations at the Kangbuk Samsung Hospi-
tal Healthcare Centers in Seoul and Suwon, South Korea. 
Our study included all KSHS participants who had under-
gone cardiac CT scanning and baPWV measurements 
as part of their chosen comprehensive health-screening 
examination from March 2010 to December 2013 (Fig. 1). 
A total of 2650 subjects had CAC on baseline and serial 
follow-up scans performed approximately 2.7 ± 0.5 years 
apart. Among them, 1,600 subjects underwent baseline 
baPWV during the same period as the first CT scan. We 
excluded 97 subjects with a history of definite cardio-
cerebro-peripheral vascular disease (n = 52), low ankle-
brachial index (ABI) (n = 1), or malignancy (n = 44). An 
additional 379 subjects were excluded because of missing 
data for the variables included in this study. Finally, total 
1124 subjects were included in this analysis (1067 men 
and 57 women; mean age, 43.6 ±  5.1  years). This study 
was approved by the Institutional Review Board of the 
Kangbuk Samsung Hospital.
Data collection
All examinations were conducted at the Kangbuk Sam-
sung Health Screening Center clinics in Seoul and Suwon 
by trained personnel, following a standardized protocol. 
A self-administered questionnaire was used to collect 
information about sociodemographic characteristics, 
lifestyle factors, medical history, family history, and med-
ication use. Body mass index (BMI) was calculated as 
weight in kilograms divided by height in meters squared. 
Trained examiners measured blood pressure in the sit-
ting position at least three times using an automated 
oscillometric device. Blood was drawn from participants 
after fasting for ≥10  h and analyzed at the Laboratory 
Medicine Department at the Kangbuk Samsung Hos-
pital. Diabetes was defined as a self-reported history of 
diabetes, the use of glucose-lowering medications, and/
or HbA1c ≥6.5 %.
BaPWV was recorded in the supine position using a 
VP-1000 (OMRON, Kyoto, Japan), which measures bilat-
eral brachial and posterior tibial artery pressure wave-
forms using an oscillometric method with cuffs placed on 
both arms and ankles. BaPWV was calculated automati-
cally for each arterial segment as the path length divided 
by the corresponding time interval. A validation study of 
baPWV measurements in an Asian population reported 
interobserver and intraobserver correlation coefficients 
of 0.98 and 0.87, respectively [19]. The coefficients of 
variation in our sample for left and right baPWV were 
12.3 and 12.6  %, respectively. The average baPWV was 
adopted as the mean of the right and left measurements 
and used for the analyses.
CT scans were obtained using a Lightspeed VCT XTe-
64 slice MDCT scanner (GE Healthcare, CA, USA). All 
scans used the same standard scanning protocol (2.5 mm 
slice thickness, 400  ms rotation time, 120  kV tube volt-
age, and 124 mAS ECG-gated dose-modulated tube cur-
rent (310  mA  ×  0.4  s)). CAC was scored following the 
standard Agatston method [20]. CAC measurements had 
interobserver and intra-observer intraclass correlation 
coefficients of 0.99 under this protocol. CAC values were 
scored by a certified CT technologist and were subse-
quently blindly overread by a board-certified at least two, 
radiologist with sufficient experience.
Statistical analysis
Demographic characteristics and cardiovascular risk 
factors of the study participants were calculated and 
stratified by baPWV quartiles. Categorical variables are 
presented as number (%) and continuous variables as 
mean (standard deviation [SD]) or median (interquar-
tile range [IQR]) based on the distribution of data. Dif-
ferences across quartiles were tested using Chi square 
or analysis of variance (ANOVA) tests. The distribution 
of continuous variables was evaluated, and right-skewed 
variables (triglycerides, alanine transaminase [ALT], 
gamma-glutamyltransferase [GTP], and high-sensitivity 
C-reactive protein [hsCRP]) were log transformed for the 
one-way ANOVA. To test for linear trends, we included 
the median value of each category as a continuous vari-
able in the regression model. To evaluate the association 
of CAC progression across baPWV quartiles, we used 
a binomial logistic regression model to estimate odds 
ratios (ORs) with 95  % confidence intervals (CIs) for 
CAC progression. We used three models to progressively 
adjust for potential confounders. We initially adjusted for 
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age. Model 1 was further adjusted for sex, center, year of 
screening examination, smoking status, alcohol intake, 
educational level, BMI, diabetes, hypertension, and 
high-density lipoprotein (HDL), low-density lipoprotein 
(LDL), and glucose levels. In model 2, we further adjusted 
for systolic blood pressure and heart rate. Finally, we ana-
lyzed the impact of baPWV and pulse pressure (PP) on 
CAC progression by dividing subjects into two groups 
according to median baPWV and PP values.
A two-sided P value <0.05 was considered significant. 
Statistical analyses were performed using Stata version 
12 (Stata Corp. 2011, College Station, TX, USA).
Results
A total of 1124 subjects had CAC on baseline and follow-
up scans performed approximately 2.7 ± 0.5 years apart. 
Their mean age was 43.6  years, and 94.9  % were men; 
31.8 % of subjects were current smokers, 8.2 % had diabe-
tes, and 24.6 % had hypertension. Mean CAC scores were 
17.8  ±  81.8 at baseline and 29.2  ±  114.9 at follow-up. 
Study participants in the highest baPWV quartiles were 
more likely to be older, male, or heavy drinkers and have 
diabetes or hypertension; higher blood pressure, glucose, 
total cholesterol, triglyceride, ALT, GTP, and CRP; and 
lower HDL (Table 1).
During the median 2.7-year follow-up period, 318 sub-
jects (28.3  %) had an increased CAC score at follow-up 
examination compared with baseline. CAC progres-
sion was seen in 76 of 835 subjects (9.1 %) with baseline 
CAC = 0 but in 242 of 289 subjects (83.7 %) with base-
line CAC > 0. Compared with subjects with no change in 
CAC values, those with an increase in CAC levels were 
more likely to be older, male, obese, or heavy drinkers 
and have diabetes or hypertension; higher BMI, blood 
pressure, fasting glucose, LDL, ALT, GTP, or CRP; and 
lower HDL cholesterol (Table  2). Study participants in 
the highest baPWV quartiles were more likely to have 
more severe progression of CAC compared with those in 
the lower baPWV quartiles (Table 3).
In multivariate logistic regression analysis, baseline 
PWV was significant correlated with CAC progres-
sion during follow-up, especially among subjects in the 
third and fourth quartiles (adjusted OR, 2.04; 95  % CI 
1.33–3.15 and OR, 2.14; 95 % CI 1.34–3.41, respectively) 
Kangbuk Samsung Healthy Study, 2010-2013
Subjects with serial Coronary Artery Calcium Scanning (median interval, 2.7 years)
N = 2,650
Subjects with baseline brachial-ankle Pulse Wave Velocity
N = 1,600
Final study sample after exclusion
N = 1,124
Exclusion 
if, data missing on at least one of the variables included in the analysis, 
N =  379
if, history of previous cardio-cerebro-peripheral vascular disease
N = 52
if, history of malignancy
N = 44
if, low ankle-brachial index (<0.90)
N = 1
Fig. 1 Study population. This flowchart summarizes the source and study population of this study
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compared with those in the lowest quartile (P for trend 
<0.001) (Table 4). In diabetic patients, these associations 
remained significant for subjects in the third and fourth 
quartiles (adjusted OR, 3.50; 95 % CI 1.80–5.20 and OR 
3.85; 95  % CI 1.88–5.82, respectively). Another analy-
ses using SQRT method to determine CAC progression 
and baPWV also showed significant correlation between 
them (Additional file 1: Tables 1, 2). Using a cutoff point 
of 10 in CAC change, the progression of CAC was still 
significantly associated with baseline baPWV (Additional 
file 1: Table 3).
Among study subjects with baseline CAC = 0, higher 
baPWV could better predict the likelihood of CAC pro-
gression compared with lower baPWV quartile values 
(Table  5), although baseline PP could not predict CAC 
progression (higher PP group, adjusted hazard ratio 
[HR], 0.92; 95 % CI 0.63–1.27, compared with lower half 
of PP). After analyzing the interaction between PP and 
PWV, PP was still not a significant predictor or CAC 
progression. Only higher PWV (>50  %), regardless of 
PP, was significantly associated with CAC progression 
(Table 6).
In multivariate analysis, progression to CAC > 0 among 
835 subjects with CAC = 0 was associated with male sex 
(OR 3.10; 95  % CI 2.25–3.95; P  <  0.001), diabetes (OR 
1.90; 95 % CI 1.05–2.85; P = 0.004), and higher PWV (OR 
1.85; 95 % CI 1.20–2.45; P = 0.001). However, among the 
289 individuals with baseline CAC > 0, only the presence 
of CAC itself (OR, 14.85; 95 % CI 12.10–17.25; P < 0.001) 
rather than other CAD risk factors was predictive of 
CAC progression.
Discussion
Our study clearly demonstrates that arterial stiffness, 
measured by baPWV, can predict progression of CAC in 
Korean adults and suggests that noninvasive, nonradiat-
ing, and readily available baPWV could be a better sur-
rogate marker of CAC progression than PP. The findings 
of our study are consistent with those of other studies 
showing a significant association between several surro-
gate markers of arterial stiffness (measured using various 
parameters) and CAC [14, 16, 17, 21, 22].
Several clinical risk factors including microalbumi-
nuria or statin use are related to CAC incidence and 
Table 1 Baseline characteristics of study participants by brachial-ankle pulse wave velocity quartiles
Data are a  means (standard deviation), d medians (interquartile range), or percentages
SI unit conversion (multiply the conversion factors to obtain the SI unit): glucose, 0.0555 (mmol/L); Total cholesterol, 0.0259 (mmol/L); LDL-C, 0.0259 (mmol/L); HDL-C, 
0.0259 (mmol/L); Triglyceride, 0.0113 (mmol/L); C-reactive protein, 10 (mg/L)
ALT alanine aminotransferase, GTP glutamyl transpeptidase, BMI body mass index, BP blood pressure, HDL-C high-density lipoprotein-cholesterol, b ≥20 g/day;  
c ≥College graduate
Characteristics PWV quartiles P for trend
Q1 Q2 Q3 Q4
PWV (cm/sec) 977–1256.5 1256.5–1345.5 1345.5–1441.5 1441.5–2397.5 <0.001
Number 281 281 282 280
Age (years)a 42.3 (4.5) 43.3 (4.3) 43.8 (5.2) 45.0 (6.0) <0.001
Male (%) 89.7 94.0 96.8 99.3 0.001
BMI (kg/m2) 25.1(3.3) 24.9 (2.8) 25.1 (3.2) 25.4 (2.9) 0.155
Obesity (%) 43.8 47.1 53.6 52.9 0.012
Current smoker (%) 26.3 31.0 30.9 33.9 0.065
Alcohol intake (%)b 28.1 32.4 32.3 40.7 0.003
High education level (%)c 84.2 82.3 87.7 80.8 0.655
Diabetes (%) 5.0 6.4 9.6 16.1 <0.001
Hypertension (%) 10.3 23.8 26.2 42.9 <0.001
Systolic BP (mmHg)a 113.9 (10.8) 118.7 (11.5) 119.3 (11.2) 126.5 (11.5) <0.001
Diastolic BP (mmHg)a 72.6 (8.1) 76.0 (8.8) 76.5 (8.0) 81.5 (9.0) <0.001
Glucose (mg/dL)a 94.4 (11.1) 98.1 (18.3) 99.2 (18.1) 105.3 (23.6) <0.001
Total cholesterol (mg/dL)a 203.5 (37.4) 212.0 (35.5) 213.6 (39.5) 210.8 (37.5) 0.020
LDL‑C (mg/dL)a 126.4 (34.1) 133.5 (32.3) 134.6 (34.6) 130.1 (33.8) 0.174
HDL‑C (mg/dL)a 53.2 (13.8) 50.5 (10.7) 49.7 (11.4) 51.0 (12.0) 0.022
Triglycerides (mg/dL)d 114 (80–156) 138 (98–192) 139 (99–200) 163 (114–227.5) <0.001
ALT (U/l)d 22 (16–31) 24 (18–35) 27 (20–41) 28 (20–42) <0.001
GTP (U/l)d 29 (19–43) 35 (24–54) 40 (26–58) 41 (28.5–68) <0.001
C‑reactive protein (mg/L)d 0.05 (0.03–0.12) 0.06 (0.04–0.11) 0.07 (0.04–0.11) 0.07 (0.04–0.14) 0.005
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progression, especially in patients with diabetes mellitus 
[23–26]. CAC nearly inevitably progress, with limited 
influence of traditional risk factors, so prediction or cal-
culation of progression of CAC might be important [25, 
27]. Because CAC scanning using MDCT is a test com-
monly used in clinical practice as a single examination 
rather than serial examinations, performance of multiple 
CAC tests in the same setting might be impracticable and 
hazardous owing to radiation exposure. Although serial 
measurements of CAC might be meaningful, no inter-
vention, including statin therapy [28], has been shown 
to slow CAC progression, and serial measurements of 
CAC are of unproven clinical value. On the other hand, 
baPWV is a relatively simple, noninvasive, nonradiat-
ing, and readily available combined measure of central 
and peripheral arterial stiffness. Unlike carotid–femoral 
pulse wave velocity, which is a measure of central arterial 
stiffness, baPWV is a combined measure of central and 
peripheral arterial stiffness. BaPWV may provide infor-
mation similar to that derived from central PWV [15] 
and is independently associated with the presence and 
severity of CAC [16, 17, 29]. Our study shows a signifi-
cant correlation between baPWV and CAC progression 
in apparently healthy subjects. From a clinical perspec-
tive, this convenient, nonradiating, and easily available 
tool may help identify CAC progression, irrespective of 
CAC presence.
Several plausible mechanisms may be responsible 
for the association between baPWV and coronary ath-
erosclerosis as expressed by CAC. First, some common 
risk factors possibly contribute to arterial stiffness and 
atherosclerosis, and this is more likely in the periph-
eral arteries. ABI is also associated with the incidence 
and severity of coronary atherosclerosis [30]. Secondly, 
given that the aorta forms a large portion of the arterial 
tree over which baPWV is measured, 58  % of the vari-
ation in baPWV can be explained by aortic PWV [15]. 
Thus, baPWV is not only a marker of peripheral arte-
rial stiffness but also an indirect marker of central arte-
rial stiffness. Thirdly, arterial stiffness could increase 
the mechanical shear stress on the arterial wall side and 
cardiac afterload. This can trigger the initial pathophysi-
ologic cascade, which leads to atherosclerotic changes 
and cardiac remodeling.
Diabetes mellitus is associated with an increased risk 
of arterial stiffness and atherosclerotic cardiovascular 
Table 2 Baseline characteristics of  study participants 
by Coronary Calcium Score change in serial examination
Data are a means (standard deviation), dmedians (interquartile range), or 
percentages
SI unit conversion (multiply the conversion factors to obtain the SI unit): glucose, 
0.0555 (mmol/L); Total cholesterol, 0.0259 (mmol/L); LDL-C, 0.0259 (mmol/L); 
HDL-C, 0.0259 (mmol/L); Triglyceride, 0.0113 (mmol/L); C-reactive protein, 10 
(mg/L)
ALT alanine aminotransferase, GTP glutamyl transpeptidase, BMI body mass 
index, BP blood pressure, HDL-C high-density lipoprotein-cholesterol; b ≥20 g/
day; c ≥College graduate
Characteristics CAC change P for trend
CAC change = 0 CAC change >0
Number 806 318
Age (years)a 42.9 (5.0) 45.3 (5.2) <0.001
Male (%) 93.1 99.7 <0.001
BMI (kg/m2) 24.9 (3.0) 25.8 (2.9) <0.001
Obesity (%) 45.4 59.1 <0.001
Current smoker (%) 32.5 30.9 0.605
Alcohol intake (%)b 32.3 38.7 0.018
High education level 
(%)c
82.9 86.2 0.188
Diabetes (%) 7.1 14.5 <0.001
Hypertension (%) 21.8 35.9 <0.001
Systolic BP (mmHg)a 118.9 (12.3) 121.3 (11.4) 0.003
Diastolic BP (mmHg)a 76.1 (9.1) 77.9 (8.7) 0.002
Glucose (mg/dL)a 97.6 (16.4) 103.4 (23.2) <0.001
Total cholesterol  
(mg/dL)a
206.4 (37.1) 219.1 (37.6) <0.001
LDL‑C (mg/dL)a 127.9 (33.0) 139.5 (34.5) <0.001
HDL‑C (mg/dL)a 51.7 (12.4) 49.6 (11.0) <0.001
Triglycerides  
(mg/dL)d
130 (90–191) 153 (113–215) <0.010
ALT (U/l)d 25 (18–37) 28 (20–40) <0.001
GTP (U/l)d 34 (22–54) 40 (27–65) <0.001
C‑reactive protein 
(mg/L)d
0.06 (0.03–0.11) 0.07 (0.04–0.13) 0.022
Table 3 Degree of change in Coronary Calcium Score according to brachial-ankle pulse wave velocity quartiles
Characteristics PWV quartiles P for trend
Q1 (N = 281) Q2 (N = 281) Q3 (N = 282) Q4 (N = 280)
Amount of interval change <0.001
 No interval change 232 219 184 171
 1–9 117 19 33 31
 10–99 29 38 59 60
 ≥100 3 5 6 18
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Table 4 The risk of progression of Coronary Calcium Score according to baseline brachial-ankle pulse wave velocity quar-
tiles odds ratio (95 % CI) of CAC change >0 by PWV quartiles
OR odds ratio, CI confidence interval
a Estimated from logistic regression. Multivariable model 1 was adjusted for age, sex, center, year of screening exam, smoking status, alcohol intake, educational level, 
BMI, diabetes, hypertension, HDL, LDL and glucose; model 2: model 1 plus adjustment for sbp and heart rate
Number Cases Age-adjusted ORa (95 % CI) Multivariate-adjusted ORa
(95 % CI)
Model 1 Model 2
Total
 Q1 281 47 1.00 (reference) 1.00 (reference) 1.00 (reference)
 Q2 281 63 1.29 (0.84–1.98) 1.12 (0.72–1.75) 1.16 (0.74–1.82)
 Q3 282 99 2.31 (1.54–3.47) 1.95 (1.27–2.99) 2.04 (1.33–3.15)
 Q4 280 109 2.34 (1.55–3.52) 1.90 (1.22–2.95) 2.14 (1.34–3.41)
 P for trend <0.001 0.001 <0.001
Table 5 Risk of progression of Coronary Calcium Score according to baseline brachial-ankle pulse wave velocity quartiles 
odds ratio (95 % CI) of CAC change >0 by PWV quartiles among subjects with baseline CAC = 0
OR odds ratio, CI confidence interval
a Estimated from logistic regression. Multivariable model 1 was adjusted for age, sex, center, year of screening exam, smoking status, alcohol intake, educational level, 
BMI, diabetes, hypertension, HDL, LDL and glucose; model 2: model 1 plus adjustment for sbp and heart rate




Model 1 Model 2
Total
 Q1 236 8 1.00 (reference) 1.00 (reference) 1.00 (reference)
 Q2 219 17 1.22 (0.93–5.27) 2.28 (0.94–5.51) 1.26 (0.93–5.50)
 Q3 202 30 4.38 (1.95–9.83) 4.21 (1.83–9.68) 1.15 (1.79–9.61)
 Q4 178 21 3.05 (1.31–7.12) 3.16 (1.29–7.70) 3.04 (1.20–7.73)
 P for trend 0.003 0.004 0.006
Table 6 Risk of progression of Coronary Calcium Score according to pulse pressure and brachial-ankle pulse wave veloc-
ity odds ratioa (95 % CI) of CAC change >0 by PWV50 % and pulse pressure 50 %
OR odds ratio, CI confidence interval
a Estimated from logistic regression. Multivariable model 1 was adjusted for age, sex, center, year of screening exam, smoking status, alcohol intake, educational level, 
BMI, diabetes, hypertension, HDL, LDL and glucose; model 2: model 1 plus adjustment for sbp and heart rate
Number Cases Age and sex-adjusted  
ORa (95 % CI)
Multivariate-adjusted ORa (95 % CI)
Model 1 Model 2
Pulse pressure
 Pulse pressure <50 % 574 159 1.00 (reference) 1.00 (reference) 1.00 (reference)
 Pulse pressure ≥50 % 550 159 1.01 (0.77–1.32) 0.91 (0.68–1.21) 0.90 (0.63–1.28)
Pulse Pressure and Pulse Wave Velocity
 PWV <50 % and pulse pressure <50 % 322 66 1.00 (reference) 1.00 (reference) 1.00 (reference)
 PWV <50 % and pulse pressure ≥50 % 240 44 0.90 (0.58–1.39) 0.85 (0.54–1.33) 0.90 (0.55–1.46)
 PWV ≥50 % and pulse pressure <50 % 252 93 2.01 (1.37–2.95) 1.82 (1.22–2.72) 1.88 (1.26–2.82)
 PWV ≥50 % and pulse pressure ≥50 % 310 115 1.88 (1.30–2.72) 1.57 (1.06–2.32) 1.75 (1.09–2.80)
 P for trend <0.001 0.002 <0.001
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disease. [31] Vascular calcification, including coronary 
artery calcification, significantly improved the predic-
tion of outcome compared with the consideration of 
traditional risk factors, [32, 33] and baPWV improved 
the ability to identify diabetic individuals at high risk of 
future cardiovascular events. [34] The combined assess-
ment of CAC and baPWV also could more effectively 
predict cardiac events than the CAC score alone [35]. 
Therefore, to predict future events, baPWV might have 
the potential for wide clinical applications, especially in 
diabetic patients.
Our study showed that PP, a surrogate marker of arte-
rial stiffness, could not predict CAC progression, unlike 
baPWV. Generally, increases in PP result from factors 
that increase and/or decrease systolic and diastolic pres-
sure, respectively. Changes in PP are mostly related to 
changes in systolic blood pressure, particularly among 
the elderly, and are usually the result of stiffness in the 
large arteries as well as an early pulse wave reflection. 
Although increases in peripheral vascular resistance 
appear to be a relatively more important component 
of hypertension in younger patients (younger than 
50  years), the role of peripheral vascular resistance in 
hypertension diminishes progressively with age [36, 
37]. Given the known effects of aging on vessel stiffness, 
increases in PP in older patients result from aortic stiff-
ening, whereas increases in younger patients are more 
likely to result from increases in stroke volume. Subjects 
in our cohort had an average age of 43.6  years, which 
means that higher PP is not likely related to higher arte-
rial stiffness and as a result is not associated with CAC 
progression.
In our study, during the follow-up period of 
2.7  ±  0.5  years, approximately 9.1  % of subjects 
(76/835) with CAC  =  0 at baseline had increases in 
CAC, whereas CAC progression was observed in 
83.7 % of subjects (242/289) with a baseline CAC > 0. 
This conversion rate is very similar to that reported 
in a previous study [38]. In that study, 106 of 422 sub-
jects (25.1  %) with no baseline CAC had a positive 
CAC score during the follow-up period. Conversion 
from a CAC score of 0 to >0 occurred in 2 (0.5 %), 5 
(1.2  %), 24 (5.7  %), 26 (6.2  %), and 49 (11.6  %) sub-
jects after 1, 2, 3, 4, and 5 years of follow up, respec-
tively [38]. Our study also showed that the presence 
of diabetes, male sex, and higher baPWV were associ-
ated with CAC progression in subjects with baseline 
CAC = 0 whereas in subjects with baseline CAC > 0, 
only the presence of CAC could predict CAC progres-
sion. So far, no clinical factor seems to mandate repeat 
CAC scanning, but baPWV is able to help predict 
CAC progression.
Limitations
The chief limitation of our study was a lack of data regard-
ing how patients with normal CAC values were treated 
by their physicians. The treatment of risk factors such as 
hypertension, diabetes, or dyslipidemia was left to the dis-
cretion of the physicians and subjects, which could have 
resulted in significant treatment bias. Thus, it is difficult 
to determine the magnitude of any confounding effects of 
treatment for risk factors that may have altered the natu-
ral course of CAC progression. Additional unmeasured 
confounders that can modify calcification processes, such 
as fetuin A, novel inflammatory markers, and additional 
risk factors (e.g., renal failure, thyroid status, or family his-
tory), may mediate this accelerated risk. This study did not 
evaluate such markers but instead limited its evaluation 
to the association between baPWV and CAC progres-
sion. Secondly, the study design was cross-sectional, which 
might preclude casual correlation. Thirdly, arterial stiffness 
was measured using baPWV, for which there is a relative 
lack of scientific evidence compared with carotid-femoral 
PWV, the gold standard of arterial stiffness measurement. 
However, previous studies have shown a high correlation 
between baPWV and aortic PWV [39]. Currently, baPWV 
is widely used in Asia, and evidence of its value is growing 
with time. Fourthly, our study comprised Korean adults 
voluntarily attending a health-screening program and was 
primarily performed in men, a small proportion of whom 
had diabetes. Fifthly, a CAC score between 0 and 10 is 
likely to represent noise. Although the reproducibility of 
CAC scores is high, the reproducibility of scores between 
0 and 9 is an issue. As compared to those who scored 10 
or greater, variation was very high among subjects who 
scored between 0 and 9, which might have had a signifi-
cant impact on our results. Finally, our follow-up period 
was relatively short, without evaluation of clinical out-
comes, which gives our findings limited generalizability.
Conclusions
Higher arterial stiffness measured by baPWV could be 
significantly associated with CAC progression.
Additional file
Additional file 1: Table 1. The Risk of Progression of Coronary Cal‑
cium Score According to Baseline Brachial‑Ankle Pulse Wave Velocity: 
Odds Ratio (95 % Confidence Interval) of Difference [√CAC(follow‑up) − 
√CAC(baseline)] >2.5 by Pulse Wave Velocity quartiles—The SQRT Analysis. 
Table 2. The Risk of Progression of Coronary Calcium Score According to 
Pulse Pressure and Brachial‑ankle Pulse Wave Velocity: Odds ratio (95 %  
Confidence Interval) of Difference [√CAC(follow‑up) − √CAC(baseline)] >2.5 by 
Pulse Wave Velocity  50 % and pulse pressure 50 %—The SQRT Analysis. 
Table 3. The Risk of Progression of Coronary Calcium Score According to 
Baseline Brachial‑Ankle Pulse Wave Velocity: Odds ratio (95 % Confidence 
Interval) of  Coronary Calcium Score Change change  >=10 by Pulse Wave 
Velocity Quartiles.
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